Prophylactic, Therapeutic, and Diagnostic Remedy for Treatment of Colibacillosis Infection (RFT-21)
Scientists at North Dakota State University have cloned and sequenced the iss (increased serum survival) gene from virulent avian Escherichia coli strains and expressed its encoded ISS polypeptide sequence. This has enabled them to conduct studies in understanding the gene's potential and devise strategies to detect and control the colibacillosis infection that the gene is believed to cause.
This invention pertains to the application of this study in formulating DNA vaccines and immunogenic compositions for providing adequate prophylactic, therapeutic and diagnostic remedies against the colibacillosis infection in humans and avian organisms.
US Patent No. 6,087,128 "DNA Encoding an Avian E. Coli ISS"
US Patent No. 6,187,321 "Avian E. Coli ISS Polypeptide"
Henry Nowak, Technology Manager
RFT, 21, RFT21
Inquire about this technology >